Gary N. Keller, CLP is Senior Consultant for Foresight Science and Technology with expertise in commercialization, intellectual asset management, and international businesses development. Keller has more than 35 years of experience in scientific innovation including corporate development and startups, technology commercialization, fundraising, sales and marketing. He has extensive experience in the commercialization of technologies for public and private companies, government laboratories, and academic institutions. He has been engaged in the development, funding and launch of numerous biotechnology startup companies and products. Keller has designed and established commercialization initiatives for large companies, institutions, organizations, states, and countries.
Keller has served in senior management roles for numerous early stage companies including Vice President Business Development and Licensing for Identify BioSensors Inc., a biotech company developing next generation of low-power biosensors for real-time monitoring of materials harmful to humans. Previously Keller was CEO of Captis Diagnostics, a Pittsburgh based cancer diagnostic company based on extracellular vesicle (EV) isolation. Prior he served as Chief Business Officer for Cells for Cells and Regenero, two Chilean Cell Therapy companies building infrastructure and leading licensing and partnering efforts. Previously he was President and Managing Director of the Midwest University Research Network (MRUN) and Cofounder and Board Chairman of H20TECH, an EPA Water Innovation Cluster for the Southeast U.S. He is author of the World Intellectual Property Organization (WIPO) Guide to Commercialization of Intellectual Property and global workshops. His startups include Immunity Bio (IBRX NASDAQ), a San Diego based Immuno-oncology Company based on a clonal Natural Killer Cell line (NK-92) and Brinks Biologics, the licensing spinoff company.
As Founding Executive Director, he launched and built the Florida Institute for Commercialization of Public Research, developing and supporting life science startups as part of Florida’s bioeconomy and started the affiliated Seed Fund. Prior, he established the role of National Manager for Cellular Therapy for Lonza Walkersville (BioWhittaker/Cambrex) as an intrapreneur within the company for the development of this market. Among other leadership roles he was the Emerging Enterprise Committee Founding Chairman for LES USA Canada, served an extended term as Life Science Committee Chairman for LESI globally, and 8 years as a board member of Sinai Health System (Chicago). Keller served on the Advisory Board of WIPO Health and WIPO GREEN and the Penn State Leadership Board. He has a B.S. in Biotechnology from Pennsylvania State University and a M.S in Biotechnology between Northwestern University and Kellogg School of Business focused on Cell Therapy and Bioinformatics and is a Certified Licensing Professional.